Main menu button

Alzinova AB

Alzinova is developing a vaccine against the group of substances that are thought to cause Alzheimer’s disease (so-called oligomers consisting of amyloid-beta-42). The vaccine, ALZ-101, is now tested in the clinical phase. The goal is to then find a partner.

Research: September 17, 2020 (SE)
Industry: Biotech
Exchange: First North Growth Market
Ticker: ALZ:SS
Markus Augustsson
Markus Augustsson LinkedIn
Head of Equity Research

Other Researches